Literature DB >> 9864174

Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma.

M Q Lacy1, K A Donovan, J K Heimbach, G J Ahmann, J A Lust.   

Abstract

We investigated whether interleukin-1beta (IL-1beta) is differentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients because IL-1beta appears to play a major role in the development of lytic bone lesions, the major clinical feature distinguishing MGUS from myeloma. In situ hybridization (ISH) for IL-1beta was performed using bone marrow aspirates from 51 MM, 7 smoldering MM, 21 MGUS, and 5 normal control samples. Using the ISH technique IL-1beta mRNA was detectable in the plasma cells from 49 of 51 patients with active myeloma and 7 of 7 patients with smoldering myeloma. In contrast, 5 of 21 patients with MGUS and 0 of 5 normal controls had detectable IL-1beta message. Bone lesions were present in 40 of the 51 MM patients analyzed, and all 40 patients had IL-1beta mRNA by ISH. These results show that greater than 95% of MM patients but less than 25% of MGUS patients are positive for IL-1beta production. In the future, continued follow-up of IL-1beta positive and negative MGUS patients should determine whether aberrant expression of plasma cell IL-1beta is predictive of those MGUS patients that will eventually progress to active myeloma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864174

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Soluble molecules and bone metabolism in multiple myeloma: a review.

Authors:  Gabriele Zoppoli; Enrico Balleari; Riccardo Ghio
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 2.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

3.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.

Authors:  John A Lust; Martha Q Lacy; Steven R Zeldenrust; Angela Dispenzieri; Morie A Gertz; Thomas E Witzig; Shaji Kumar; Suzanne R Hayman; Stephen J Russell; Francis K Buadi; Susan M Geyer; Megan E Campbell; Robert A Kyle; S Vincent Rajkumar; Philip R Greipp; Michael P Kline; Yuning Xiong; Laurie L Moon-Tasson; Kathleen A Donovan
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

4.  Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.

Authors:  Tatjana I Jung; Falk Hoffmann; Gerd Glaeske; Dieter Felsenberg
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-22       Impact factor: 4.553

5.  Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.

Authors:  Ulrike Heider; Ivana Zavrski; Christian Jakob; Katharina Bängeroth; Claudia Fleissner; Corinna Langelotz; Kurt Possinger; Lorenz C Hofbauer; Volker Viereck; Orhan Sezer
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

6.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

7.  Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.

Authors:  G Tsirakis; C A Pappa; M Kaparou; V Katsomitrou; A Hatzivasili; T Alegakis; A Xekalou; E N Stathopoulos; M G Alexandrakis
Journal:  Eur J Histochem       Date:  2011-08-27       Impact factor: 3.188

Review 8.  The emerging roles of inflammasome-dependent cytokines in cancer development.

Authors:  Hanne Van Gorp; Mohamed Lamkanfi
Journal:  EMBO Rep       Date:  2019-05-17       Impact factor: 8.807

Review 9.  An update of novel therapeutic approaches for multiple myeloma.

Authors:  Paul Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Curr Treat Options Oncol       Date:  2004-06

10.  Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.

Authors:  Jingnan Sun; Xue Wen; Fengyan Jin; Yuying Li; Jifan Hu; Yunpeng Sun
Journal:  Onco Targets Ther       Date:  2015-09-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.